Abstract
Background/Objectives: The effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on plasma concentrations of adiponectin, a fat-derived hormone with anti-atherogenic and anti-inflammatory properties, is uncertain. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to investigate this association in humans. Methods: RCTs investigating the impact of DPP-4 inhibitors on plasma adiponectin concentrations were identified after searching PubMed-Medline, SCOPUS, and Google Scholar databases (up to February 2015). As quantitative data synthesis methods, the random-effects model and the generic inverse variance method were applied. Standard methods of meta-regression, sensitivity analysis, and publication bias assessments were performed. Results: Eight RCTs with nine treatment-arms were included. Meta-analysis did not suggest a significant pooled effect of DDP-4 inhibitors on adiponectin values (weighed-mean-difference [WMD]: 0.19 μg/mL, 95%CI: -0.50, 0.88). However, a significant elevation of plasma adiponectin concentrations was observed in the subset of trials with vildagliptin (WMD: 0.55 μg/mL, 95%CI: 0.13, 0.98, p=0.010) but not sitagliptin (WMD: -0.06 μg/mL, 95%CI: -1.13, 1.00, p=0.907). There was a significant elevation of plasma adiponectin levels in the subset of trials comparing DPP-4 inhibitors versus placebo or no treatment (WMD: 0.74 μg/mL, 95%CI: 0.36, 1.12, p <0.001) but not in the subset using hypoglycemic drugs as comparators), or using other hypoglycemic drugs (WMD: -0.18 μg/mL, 95%CI: -0.99, 0.62, p=0.654). No significant effect was found for treatment duration, confirmed by meta-regression analyses. Conclusion: DPP-4 inhibitors cause a significant increase in plasma adiponectin concentrations and this effect is greater with vildagliptin than sitagliptin.
Keywords: Adiponectin, Cardiovascular diseases, Dipeptidyl peptidase-4 inhibitors, Meta-analysis, Systematic review, Type 2 diabetes mellitus.
Current Medicinal Chemistry
Title:Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Volume: 23 Issue: 13
Author(s): Amirhossein Sahebkar, Valentina Ponzo and Simona Bo
Affiliation:
Keywords: Adiponectin, Cardiovascular diseases, Dipeptidyl peptidase-4 inhibitors, Meta-analysis, Systematic review, Type 2 diabetes mellitus.
Abstract: Background/Objectives: The effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on plasma concentrations of adiponectin, a fat-derived hormone with anti-atherogenic and anti-inflammatory properties, is uncertain. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to investigate this association in humans. Methods: RCTs investigating the impact of DPP-4 inhibitors on plasma adiponectin concentrations were identified after searching PubMed-Medline, SCOPUS, and Google Scholar databases (up to February 2015). As quantitative data synthesis methods, the random-effects model and the generic inverse variance method were applied. Standard methods of meta-regression, sensitivity analysis, and publication bias assessments were performed. Results: Eight RCTs with nine treatment-arms were included. Meta-analysis did not suggest a significant pooled effect of DDP-4 inhibitors on adiponectin values (weighed-mean-difference [WMD]: 0.19 μg/mL, 95%CI: -0.50, 0.88). However, a significant elevation of plasma adiponectin concentrations was observed in the subset of trials with vildagliptin (WMD: 0.55 μg/mL, 95%CI: 0.13, 0.98, p=0.010) but not sitagliptin (WMD: -0.06 μg/mL, 95%CI: -1.13, 1.00, p=0.907). There was a significant elevation of plasma adiponectin levels in the subset of trials comparing DPP-4 inhibitors versus placebo or no treatment (WMD: 0.74 μg/mL, 95%CI: 0.36, 1.12, p <0.001) but not in the subset using hypoglycemic drugs as comparators), or using other hypoglycemic drugs (WMD: -0.18 μg/mL, 95%CI: -0.99, 0.62, p=0.654). No significant effect was found for treatment duration, confirmed by meta-regression analyses. Conclusion: DPP-4 inhibitors cause a significant increase in plasma adiponectin concentrations and this effect is greater with vildagliptin than sitagliptin.
Export Options
About this article
Cite this article as:
Sahebkar Amirhossein, Ponzo Valentina and Bo Simona, Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Current Medicinal Chemistry 2016; 23 (13) . https://dx.doi.org/10.2174/0929867323666160405111354
DOI https://dx.doi.org/10.2174/0929867323666160405111354 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mediterranean Diet and Longevity
Current Nutrition & Food Science L-Arginine Signalling Potential in the Brain: The Peripheral Gets Central
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Apelins in the Physiology of the Heart
Protein & Peptide Letters Alternative Therapies for Diabetes: A Comparison of Western and Traditional Chinese Medicine (TCM) Approaches
Current Diabetes Reviews Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Current Pharmaceutical Design Clinical Application of Ghrelin
Current Pharmaceutical Design Editorial (Hot Topic:Recent Advance in the Studies of Beta-glucans for Cancer Therapy)
Anti-Cancer Agents in Medicinal Chemistry Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials Methylenetetrahydrofolate Reductase: Biochemical Characterization and Medical Significance
Current Pharmaceutical Design The Brain-Immune-Gut Triangle: Innate Immunity in Psychiatric and Neurological Disorders
Current Immunology Reviews (Discontinued) Recent Clinical Trials of Pharmacologic Cardiovascular Interventions in Patients with Chronic Kidney Disease
Reviews on Recent Clinical Trials Transseptal Access to the Left Atrium: Tips and Tricks to Keep it Safe Derived from Single Operator Experience and Review of the Literature
Current Cardiology Reviews Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design PUFA for Human Health: Diet or Supplementation?
Current Pharmaceutical Design Controversies on HDL: Should it be a Target Biomarker in Patients with Lipid Disorders?
Current Vascular Pharmacology Repair of Dilated Aortic Root and Sinotubular Junction Using a Stabilizer Ring
Recent Patents on Cardiovascular Drug Discovery Smoking, Estradiol Metabolism and Hormone Replacement Therapy
Current Medicinal Chemistry - Cardiovascular & Hematological Agents COPD Management: Look Beyond the Airway Obstruction, Chronic Bronchitis and Emphysema
Current Respiratory Medicine Reviews Cholesterol Ester Transfer Protein (CETP), Postprandial Lipemia and Hypolipidemic Drugs
Current Medicinal Chemistry